Identification of New Proteins Related with Cisplatin Resistance in Saccharomyces Cerevisiae

Overview

Journal Appl Microbiol Biotechnol

Specialties Biomedical Engineering
Biotechnology
Microbiology

Date 2021 Feb 12

PMID 33576883

Citations 1

Authors

Antonio M Burgos-Molina

Silvia Mercado-Saenz

Casimiro Cardenas

Beatriz Lopez-Diaz

Francisco Sendra-Portero

Miguel J Ruiz-Gomez

Affiliations

Soon will be listed here.

Abstract

The aim of this study is to select a cisplatin-resistant Saccharomyces cerevisiae strain to look for new molecular markers of resistance and the identification of mechanisms/interactions involved. A resistant strain was obtained after 80 days of cisplatin exposure. Then, total protein extraction, purification, and identification were carried out, in wild-type (wt) and resistant strains, by tandem mass spectrometry using a "nano HPLC-ESI-MS/MS" ion trap system. The increase in the exponentially modified protein abundance index (emPAI) (resistant vs wt strains) was calculated to study the increase in protein expression. "Genemania" software ( http://www.Genemania.org/ ) was used to compare the effects, functions, and protein interactions. KEGG tool was used for metabolic pathway analysis. Data are available via ProteomeXchange with identifier PXD020665. The cisplatin-resistant strain showed 2.5 times more resistance than the wt strain for the inhibitory dose 50% (ID50) value (224 μg/ml vs 89.68 μg/ml) and 2.78 times more resistant for the inhibitory dose 90% (ID90) value (735.2 μg/ml vs 264.04 μg/ml). Multiple deregulated proteins were found in the glutathione and carbon metabolism, oxidative phosphorylation, proteasome, glycolysis and gluconeogenesis, glyoxylate metabolism, fatty acid degradation pathway, citric acid cycle, and ribosome. The most overexpressed proteins in the cisplatin-resistant strain were related to growth and metabolism (QCR2, QCR1, ALDH4, ATPB, ATPA, ATPG, and PCKA), cell structure (SCW10), and thermal shock (HSP26). The results suggest that these proteins could be involved in cisplatin resistance. The resistance acquisition process is complex and involves the activation of multiple mechanisms that interact together. KEY POINTS: • Identification of new proteins/genes related to cisplatin resistance • Increased expression of QCR2/QCR1/ALDH4/ATPB/ATPA/SCW10/HSP26/ATPG and PCKA proteins • Multiple molecular mechanisms that interact together are involved in resistance.

Citing Articles

Differential operation of MLH1/MSH2 and FANCD2 crosstalk in chemotolerant bladder carcinoma: a clinical and therapeutic intervening study.

Basu M, Mukhopadhyay D, Chakraborty B, Ghosh S, Pal D, Ghosh A Mol Cell Biochem. 2022; 478(7):1599-1610.

PMID: 36434146 DOI: 10.1007/s11010-022-04616-9.

References

Aggarwal S . A histochemical approach to the mechanism of action of cisplatin and its analogues. J Histochem Cytochem. 1993; 41(7):1053-73. DOI: 10.1177/41.7.8515048. View

Bodiga S, Vemuri P, Bodiga V . Low Ctr1p, due to lack of Sco1p results in lowered cisplatin uptake and mediates insensitivity of rho0 yeast to cisplatin. J Inorg Biochem. 2018; 187:14-24. DOI: 10.1016/j.jinorgbio.2018.07.003. View

Brozovic A, Ambriovic-Ristov A, Osmak M . The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Crit Rev Toxicol. 2010; 40(4):347-59. DOI: 10.3109/10408441003601836. View

Casares C, Ramirez-Camacho R, Trinidad A, Roldan A, Jorge E, Garcia-Berrocal J . Reactive oxygen species in apoptosis induced by cisplatin: review of physiopathological mechanisms in animal models. Eur Arch Otorhinolaryngol. 2012; 269(12):2455-9. DOI: 10.1007/s00405-012-2029-0. View

Chao C . Molecular basis of cis-diamminedichloroplatinum(II) resistance: a review. J Formos Med Assoc. 1996; 95(12):893-900. View

Chen R, Thorner J . Function and regulation in MAPK signaling pathways: lessons learned from the yeast Saccharomyces cerevisiae. Biochim Biophys Acta. 2007; 1773(8):1311-40. PMC: 2031910. DOI: 10.1016/j.bbamcr.2007.05.003. View

Costa A, Machado N, Rego A, Sousa M, Corte-Real M, Chaves S . Proteasome inhibition prevents cell death induced by the chemotherapeutic agent cisplatin downstream of DNA damage. DNA Repair (Amst). 2018; 73:28-33. DOI: 10.1016/j.dnarep.2018.10.006. View

Dasari S, Tchounwou P . Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014; 740:364-78. PMC: 4146684. DOI: 10.1016/j.ejphar.2014.07.025. View

Dempke W, Voigt W, Grothey A, Hill B, Schmoll H . Cisplatin resistance and oncogenes--a review. Anticancer Drugs. 2000; 11(4):225-36. DOI: 10.1097/00001813-200004000-00001. View

10.

Galluzzi L, Vitale I, Senovilla L, Eisenberg T, Carmona-Gutierrez D, Vacchelli E . Independent transcriptional reprogramming and apoptosis induction by cisplatin. Cell Cycle. 2012; 11(18):3472-80. PMC: 3466557. DOI: 10.4161/cc.21789. View

11.

Gibson N, McAlister-Henn L . Physical and genetic interactions of cytosolic malate dehydrogenase with other gluconeogenic enzymes. J Biol Chem. 2003; 278(28):25628-36. DOI: 10.1074/jbc.M213231200. View

12.

Huang R, Eddy M, Vujcic M, Kowalski D . Genome-wide screen identifies genes whose inactivation confer resistance to cisplatin in Saccharomyces cerevisiae. Cancer Res. 2005; 65(13):5890-7. DOI: 10.1158/0008-5472.CAN-04-4093. View

13.

Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, Rappsilber J . Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics. 2005; 4(9):1265-72. DOI: 10.1074/mcp.M500061-MCP200. View

14.

Izaguirre D, Ng C, Kwan S, Kun E, Tsang Y, Gershenson D . The Role of GDF15 in Regulating the Canonical Pathways of the Tumor Microenvironment in Wild-Type p53 Ovarian Tumor and Its Response to Chemotherapy. Cancers (Basel). 2020; 12(10). PMC: 7650722. DOI: 10.3390/cancers12103043. View

15.

Strick P, Kim C . Input to primate motor cortex from posterior parietal cortex (area 5). I. Demonstration by retrograde transport. Brain Res. 1978; 157(2):325-30. DOI: 10.1016/0006-8993(78)90035-5. View

16.

Kanehisa M, Sato Y . KEGG Mapper for inferring cellular functions from protein sequences. Protein Sci. 2019; 29(1):28-35. PMC: 6933857. DOI: 10.1002/pro.3711. View

17.

Klein T, Chang J, Cho M, Easton K, Fergerson R, Hewett M . Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J. 2002; 1(3):167-70. DOI: 10.1038/sj.tpj.6500035. View

18.

Kowalski D, Pendyala L, Daignan-Fornier B, Howell S, Huang R . Dysregulation of purine nucleotide biosynthesis pathways modulates cisplatin cytotoxicity in Saccharomyces cerevisiae. Mol Pharmacol. 2008; 74(4):1092-100. PMC: 2574737. DOI: 10.1124/mol.108.048256. View

19.

Larriba G, Basco R, Andaluz E, Luna-Arias J . Yeast exoglucanases. Where redundancy implies necessity. Arch Med Res. 1993; 24(3):293-9. View

20.

Liao C, Hu B, Arno M, Panaretou B . Genomic screening in vivo reveals the role played by vacuolar H+ ATPase and cytosolic acidification in sensitivity to DNA-damaging agents such as cisplatin. Mol Pharmacol. 2006; 71(2):416-25. DOI: 10.1124/mol.106.030494. View